WNT signaling – lung cancer is no exception

Judit Rapp 1,2, Luca Jaromi 1,2, Krisztian Kvell 1,2, Gyorgy Miskei 1,2 and Judit E. Pongracz 1,2*

Abstract
Since the initial discovery of the oncogenic activity of WNT ligands our understanding of the complex roles for WNT signaling pathways in lung cancers has increased substantially. In the current review, the various effects of activation and inhibition of the WNT signaling pathways are summarized in the context of lung carcinogenesis. Recent evidence regarding WNT ligand transport mechanisms, the role of WNT signaling in lung cancer angiogenesis and drug transporter regulation and the importance of microRNA and posttranscriptional regulation of WNT signaling are also reviewed.

Background
Lung cancer (LC) is one of the deadliest forms of cancer worldwide [1, 2] affecting both genders [3, 4]. The two main types of LC-s are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC represents 15–20% of all LC cases and is the more aggressive form; it metastasizes early and therefore surgical intervention is rarely a therapeutic option [5]. On the other hand, NSCLC denotes 80–85% and can be further classified into adeno (AC)-, squamous cell (SCC)-, large cell (LCC) and various mixed type carcinomas [6]. Unfortunately, the majority of NSCLC patients are diagnosed at an advanced stage of the disease narrowing down therapeutic options and leading to a limited median survival of about 18 months [7]. Recent studies have confirmed that therapy-surviving cancer stem cells (CSC) play a cardinal role in drug resistance and therefore, rapid progression of the disease [8]. While the carcinogenic process in the lung can be traced back to genetic mutations, malfunctioning signaling pathways are also highly important modulators of tumor formation and individual features of the disease.

An increasing amount of evidence has shown that the WNT pathway is one of the main signaling pathways involved in maintaining lung homeostasis and that aberrant activation of this pathway may underlie several debilitating lung diseases. Similarly, to other human cancers, WNT signaling plays an important part in lung carcinogenesis. Interestingly, however, while some epigenetic changes that affect WNT pathway inhibitors are similar to those seen in other malignancies, genetic mutations of the WNT pathway are uncommon in NSCLCs [9].

This review will summarize some novel aspects of WNT signaling, what is currently known about WNT associated LC pathogenesis as well as some important features of WNT mediated events in LC therapies.

The complexity of WNT signaling – Canonical and non-canonical WNT signaling pathways
WNT proteins are secreted glyco-lipoprotein morphogens that are required during lung development for cell-fate specification, cell proliferation and the control of asymmetric cell division. In adults, WNT signaling is essential for stem cell maintenance for regulation of tissue homeostasis [10]. Most of the 19 WNT ligands and the 10 main receptors, Frizzleds (FZD) that have been identified in mammalian cells can be identified in the human lung [9, 11]. The two main different WNT pathways include i) the beta-catenin-dependent or canonical pathway, and ii) the beta-catenin-independent or non-canonical pathways including the planar cell polarity (PCP) and the WNT/Ca2+ pathways (Fig. 1).

Canonical or beta-catenin dependent WNT signaling.
In the lung, the role of WNT signaling has been examined in detail by multiple studies which mostly focus on beta-catenin-dependent signaling. In the canonical pathway during the absence of WNT, a beta-catenin destruction
complex is assembled, consisting of: Axis inhibition protein (AXIN), adenomatous polyposis coli (APC), and glycogen synthase kinase 3-beta (GSK-3-beta) whereby beta-catenin is phosphorylated at serine and threonine sites and then proteolytically degraded [9, 12]. If WNT is available to bind to one of the ten FZD receptors then a receptor complex between WNT, FZD, lipoprotein receptor–related protein (LRP), Disheveled (DVL), and AXIN is formed [9]. Within this active complex, DVL becomes phosphorylated and eventually inhibits GSK-3-beta resulting in reduced phosphorylation and consequently stops the proteolytic destruction of beta-catenin. Beta-catenin subsequently accumulates in the cytoplasm. The cytoplasmic beta-catenin can then migrate to the nucleus and forms a complex with members of the T-cell factor (TCF)/Lymphoid enhancer-binding factor (LEF) family of transcription factors and transcriptional coactivators including cAMP response element-binding protein (CREB)–binding protein (CBP) and p300. The many target genes include c-myc and cyclin D1 [9]. The transmembrane receptor tyrosine kinase orphan receptor ROR2 (which is important in non-canonical WNT signaling) may also be involved in canonical signaling via interactions with FZD2 [13]. ROR2 [14], as well as the other WNT-binding receptors such as receptor-like tyrosine kinase RYK [15], can therefore act as regulatory receptors for the beta-catenin dependent WNT signaling.

**Non-canonical WNT signaling**

The two non-canonical WNT pathways are activated by several WNT ligands including WNT4, WNT5a, WNT7a, WNT11 and WNT16 [16–18]. Activation of the PCP signaling pathway, for example by WNT11, leads to the activation of the small GTPases RhoA (RAS homologue gene-family member A) and RAC1 (Ras-related C3 botulinum toxin substrate 1). This, in turn, activates the stress kinases JNK (Jun N-terminal kinase) and ROCK (Rho-associated coiled-coil-containing protein kinase 1) that initiates remodeling of the cytoskeleton thus leading to changes in cell adhesion and motility [19–21].

The best known activator of Ca2+–dependent WNT signaling is WNT5a. It triggers signal transduction via DVL-3, heterotrimeric G proteins and phospholipases [22]. Activation of this pathway leads to a transient increase in cytoplasmic free Ca2+ level that in turn can activate the protein kinase C (PKC) family, CaMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin [23]. Apart from the well-known

---

**Fig. 1** Multiplicity of canonical (a) and non-canonical (b) WNT pathways. Binding of WNT ligands to individual or different combination of their receptors including FZD and LRPS/6, or FZD in combination with ROR1, ROR2 or RYK activate multiple beta-catenin dependent (a) and beta-catenin-independent pathways (b).
Ca2+−dependent WNT signaling pathway, a novel, FYN tyrosine kinase and Signal Transducer and Activator of Transcription (STAT) transcriptional regulator-mediated non-canonical WNT signaling pathway has also been identified in tumor cells [24]. Although WNT signaling pathways seem distinct, WNT proteins are promiscuous and can share receptors and regulate the expression of WNT signaling molecules, as well as modify WNT signaling pathway activity. Non-canonical WNT signaling, for example, represses canonical WNT activity via various mechanisms involving PKC-alpha, CaMKII-Transforming growth factor beta-Activated Kinase (TAK)1, Nemo-like Kinase (NLK), Siah2 E3 ubiquitin ligase or calcineurin-NFAT [21, 25–28]. Reports describing activation of the canonical pathway by non-canonical WNT ligands also exist [21, 29] making WNT signaling difficult to decipher and even more difficult to modulate in cancer therapy.

**Functional variations of WNT signaling among cell types**

Functional analyses of the canonical and non-canonical WNT pathways revealed that the canonical, PCP and Ca2+ pathways regulate multiple cellular activities in the lung that are dependent on the specific cellular context. In most cell types, non-canonical WNT signaling regulates canonical WNT activity, which is also critical for many aspects of lung biology. In response to canonical WNT signaling for example, beta-catenin/TCF/LEF signaling is activated in different lung cell types including the primordial epithelium (PE), alveolar epithelium (AE), and adjacent mesenchyme [30]. Human tissue studies have highlighted that in the developing lung, beta-catenin is found mainly in the peripheral epithelium, LEF1 expression is detected in alveolar and bronchial epithelium, while TCF4 is observed in epithelium and mesenchyme [31]. Tissue-specific deletion of beta-catenin in lung epithelial cells of test animals led to disrupted lung morphogenesis, lack of differentiation of the peripheral lung, enhanced formation of the conducting airways and consequently to death at birth due to respiratory failure [32]. Furthermore, beta-catenin phosphorylation can also lead to respiratory defects. Phosphorylation of beta-catenin at tyrosine 489 stimulates its nuclear localization and fibroblast activation which is a characteristic feature of bronchopulmonary dysplasia [33]. While deletion of the non-canonical WNT5a causes hyper-thickening of the mesenchymal interstitium and over-branching of the epithelial airways [34], overexpression of WNT5a in the epithelium disrupts epithelial-mesenchymal interaction and causes malformations in both the airway epithelium and the surrounding mesenchyme [35]. WNT5a also has a role in epithelial-mesenchymal transition (EMT) in LC; where expression of WNT5a and its receptor FZD2 have an inverse correlation with the expression of markers of epithelial differentiation, such as EpCAM, E-cadherin or keratin. Expressions of WNT5a and FZD2 positively correlate with the expression of vimentin, N-cadherin and fibronectin, which are well-known mesenchymal markers and are used to identify EMT during carcinogenesis [36]. Consequently, constitutive activation of either the canonical or the non-canonical WNT pathways in the developing lung can result in non-differentiated, dysfunctional lung phenotypes that resemble certain subtypes of LCs [37]. In support of this, investigation of constitutive activation of beta-catenin has shown that hyperactive canonical WNT signaling may channel NSCLC carcinogenesis towards the adenocarcinoma subtype [38].

**WNT signaling in LC**

Various LC subtypes are believed to originate from stem cells in different histological parts of the lung. Adenocarcinoma, one of the NSCLC subtypes, has been reported to develop from various progenitor cells including alveolar type (AT) II cells, Clara cells, and bronchialveolar stem cells (BASCs) [39–41]. The other NSCLC subtype, squamous cell carcinoma, initiates from basal cells [42] whereas SCLC is derived from pulmonary neuroendocrine cells (PNECs) [43]. Studies using genetic manipulation, however, have proved that such “histologically localized stem cell origin” approaches in LC are oversimplified. Overexpression of RAS for example in PNECs, a cell type thought to be the origin of SCLC leads to adenocarcinoma [44], while inactivation of p53 and Rb1 in ATII cells results in SCLC instead of adenocarcinoma [45]. Such studies indicate that driver mutations are more important than the cell of origin.

**Murine cancer models**

In murine models, activation of WNT signaling is associated with increased carcinogenic potential [46] especially if activation of canonical WNT signaling is triggered parallel with KRAS mutation [47, 48]. This process is also observed in human LC [49]. In human lung adenocarcinoma cases KRAS mutations are missense mutations which introduce amino acid substitution at one of the positions 12, 13, or 61. The result of these mutations is constitutive activation of the KRAS signaling pathway and it has been shown that if activation of KRAS and WNT signaling are combined, the joint activation leads to increased tumor size [49]. While tumors in WNT1 transgenic mice regress as WNT signals are blocked, tumor growth becomes WNT-independent in p53-deficient mice [50]. In the KRAS G12D substitution induced lung adenocarcinoma mouse model, WNT signaling enhances proliferation and EMT. Also, if down-regulation of SOX2 and upregulation of SOX9 and GATA6 simultaneously accompany KRAS mutation [51] then alterations in WNT signaling do not modulate the final outcome [48].
**WNT pathway mutations differ in LC from other cancer types**

The most studied WNT pathway mutations in cancers include inherited and sporadic mutations in APC and beta-catenin genes. Since APC is part of the degradation scaffold for beta-catenin, mutations of APC result in reduced degradation and increased nuclear accumulation of beta-catenin, leading to activation of target oncogenes including cyclin D1 and c-myc [52]. Such mutations are not universal in all cancer types and while APC mutations occur more frequently in cancers of the colon, the lung is rarely affected by such mutations. A constitutively active beta-catenin-LEF1 fusion protein under tissue specific promoter control has been designed to express mutant, degradation-resistant beta-catenin to mimic the effect of mutation in the degradation scaffold [37]. The fusion protein was used to mimic the constitutive activation of beta-catenin which has also been described in cancers of the lung. Increased levels of beta-catenin [53, 54] and loss of heterozygosity on chromosome 5q, which contains the APC locus, have been observed in LC types (Table 1). While specific site mutations of the APC [55] or the beta-catenin genes are rare in LCs, LC types are much better characterized by dysregulation of WNT ligand transcription [56–58]. For example, loss of WNT7a mRNA is a frequent feature of some LC cell lines and primary tumors [59]. NSCLC cells transformed with WNT7a show inhibition of anchorage independent growth via the JNK/AP1 dependent PCP signaling pathway [60]. In some other NSCLCs, elevated levels of WNT1 [61] and WNT2 [62] have been reported. Experimental inhibition of WNT2 induced signaling leads to down-regulation of the anti-apoptotic gene, Survivin and consequently initiates apoptosis [62]. The Sox2 gene coding the SOX2 transcription factor that is essential for maintaining self-renewal is also highly expressed in the main histological types of LCs [63]. Inhibition of SOX2 expression in lung adenocarcinoma induces apoptosis of tumor cells [64] and down-regulates WNT1/2, Notch1, and c-myc gene expression. On the other hand, stabilization of beta-catenin signaling blocks Clara cell differentiation to ciliated cells [65], while deletion of beta-catenin in basal cells is able to suppress proliferation and triggers apoptosis [66]. Moreover, autocrine insulin-like growth factor-1 (IGF-1) signaling induces WNT5a dependent trans-differentiation of ATII cells to ATI-like cells [67].

**Shifts between canonical and non-canonical WNT signaling modulate the carcinogenic process.**

A shift from canonical to non-canonical WNT signaling, or vice versa, has also been reported in certain NSCLC subtypes. Up-regulation of the canonical WNT7b was detected in adenocarcinomas, while increased expression of WNT5a was found in primary squamous cell carcinomas [68]. Additionally, although any tumors are associated with EMT [69] and generally linked to increased beta-catenin-dependent signaling [70], the non-canonical WNT5a, which also regulates fibroblast growth factor (FGF) 10 and sonic hedgehog (SHH) expression [35], is overexpressed in lung metastases [71]. Matrix metalloproteinases, which are essential for tissue remodeling and are elevated in invasive cancers [72, 73], are target genes of both canonical and non-canonical WNT signaling pathways.

It is not only the WNT ligands, but also various signaling molecules that are dysregulated in LCs. For example, overexpression of DVL-3, a signal transducer molecule and positive regulator of WNT signaling pathways, was reported in 75% of primary NSCLCs compared to autologous matched normal tissue controls [74]. Down-regulation of WNT pathway antagonists, like Dickkopf-3 (DKK-3) [75], WNT inhibitory factor (WIF) [76, 77] and secreted Frizzled-Related Protein (sFRP) [78], have also been reported in various subtypes of LCs (summarized in Table 1).

**Genome-wide association studies and LC susceptibility**

Genome-wide association studies recently identified three LC susceptibility loci in chromosome regions 15q25, 5p15 and 6p21 [79]. Importantly, the nicotinic acetylcholine receptor (nAChR) subunit genes are located on the 15q25 chromosomal region. As nAChRs are expressed on bronchial cells and bind tobacco-related carcinogens with higher affinity than nicotine itself, therefore it is not surprising that the risk of LC is drastically increased in smokers [80]. Nicotinic AChRs in general, and alpha7 nAChRs in particular have been linked to nicotine-stimulated proliferation of lung carcinoma cells [81]. The nicotine induced up-regulation of WNT/PPAR-gamma (peroxisome proliferator activated receptor gamma) signaling can also regulate cigarette smoke-induced trans-differentiation of lung fibroblast to myofibroblasts that participate forming the cancer-associated stroma [82]. The BAT3 gene on the 6p21 locus affects p53 function and the cellular response to stress and apoptosis [83]. The same locus has also been associated with increased LC risk [80]. The telomerase reverse transcriptase (TERT) is located on the 5p15 locus and its modifications affects p53 function and the cellular response to stress and apoptosis [83]. The same locus has also been associated with increased LC risk [80]. The telomerase reverse transcriptase (TERT) is located on the 5p15 locus and its modifications can cause aberrant proliferation and increased LC risk in both smokers and non-smokers [84]. The TERT-mediated developmental programs are similar to Myc and WNT-mediated responses and therefore, the increased risk for proliferative diseases is not surprising [84]. Interestingly, a genome-wide association study conducted on people who had never smoked revealed a strong correlation between the reduced transcription level of the glypican-5 (GPC5) gene and genotypes of the replicated SNP (rs2352028 at 13q31.3) in lung adenocarcinomas. GPC5 is a member of the glypican gene family of heparin sulphate proteoglycans that control the signaling pathway of WNT, hedgehog (HH), fibroblast growth factors (FGFs), and bone morphogenetic proteins.
BMPs) which are all important regulators of cellular proliferation and differentiation [85].

WNT ligands are “posted” in lipid envelopes
Gradients of WNT proteins are essential for tissue maintenance. Importantly, WNT gradients lead to different gene expressions at certain points of the gradient in the tissue. Such concentration differences generated along the gradient might even explain how designated “canonical” and “non-canonical” WNT proteins can alternate between signaling pathways. How the gradient is maintained is not yet entirely clear. Due to their lipid residues, WNT proteins are highly hydrophobic; they attach tightly to cell membranes [86] and then insert

Table 1 WNT ligands and signaling molecules associated with LC

| Gene       | Function                                                                 | Mutation type/level of expression                                                                 | References |
|------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------|
| APC        | Part of beta-catenin destruction complex                                 | No mutation Suppressed expression by promoter methylation                                       | [184]      |
| AXIN       | Negative regulator of WNT signaling, Promotes beta-catenin phosphorylation which leads to beta-catenin degradation | No mutation Reduced expression                                                                  | [185]      |
| CTNNB1     | Main component of canonical signaling, it serves as a transcription activator, binding to TCF/LEF family | Missense mutation of exon 3 results in substitution of Ser/Thr residues                           | [38]       |
|            |                                                                         | No mutation Increased expression in cytoplasm and nuclear compartment associated with poor prognosis | [186]      |
| DKK1       | Binding to LRPS/6 leads to its endocytosis and inhibition of canonical signaling | Increased expression detected in serum                                                          | [187]      |
| DKK3       | Secreted WNT antagonist                                                  | No mutation Reduced expression                                                                  | [188]      |
| DVL1       | Required for FZD induced signaling pathway activation                    | No mutation Increased expression associated with advanced stages                               | [189]      |
| DVL2       |                                                                         | No mutation Increased expression is associated with advanced stages                            | [189]      |
| DVL3       |                                                                         | No mutation Increased expression                                                                | [190]      |
| FZD8       | Receptor for WNT proteins                                               | No mutation Increased expression                                                                | [191]      |
| GSK-3-beta | Phosphorylates beta-catenin resulting in beta-catenin degradation        | No mutation Ser9 phosphorylation is associated with poor prognosis                               | [192]      |
| SFRP1      | Inhibits WNT signaling by binding to WNT proteins                       | No mutation Reduced expression regulated by promoter hypermethylation                           | [193]      |
| TCF4       | Transcription factor that complexes with beta-catenin upon activated canonical WNT signaling | No mutation Increased expression in poorly differentiated tumor                                 | [194]      |
| WIF1       | Binding to WNT proteins to prevent their interaction with receptors     | No mutation Increased expression                                                                | [195]      |
| WNT1       | Non-canonical WNT ligand                                                | No mutation Increased expression in NSCLC                                                       | [196]      |
| WNT11      | WNT ligand which can activate both canonical and non-canonical WNT pathway | No mutation Increased expression                                                               | [68]       |
| WNT2       | Canonical WNT ligand                                                    | No mutation Increased expression                                                                | [197]      |
| WNT3       | Canonical WNT ligand                                                    | No mutation Increased expression                                                                | [107]      |
| WNT5A      | Non-canonical WNT ligand                                                | No mutation Increased expression in SCC                                                          | [134]      |
| WNT7A      | Non-canonical WNT ligand                                                | No mutation Reduced expression due to promoter hypermethylation                                 | [198]      |
| WNT7B      | Canonical WNT ligand                                                    | No mutation Increased expression in AC                                                           | [199]      |

Most of the WNT pathway associated molecules are not mutated but the WNT signaling pathway is deregulated
themselves into the lipid bilayer. If the lipid residues are removed from the amino acid backbone, WNT proteins become biologically inactive [87]. Due to their lipid modifications, WNT ligands understandably cannot be directly secreted into aqueous body fluids (Fig. 2). Recent studies indicate that WNT signals are most likely to be transduced via lipid-coated particles including extracellular vesicles [88]. For decades, extracellular vesicles or exosomes have been disregarded as a potential route of cellular communication, but recently they have leaped into the center of interest. Lipid envelopes can influence long-range WNT signal gradients [89] via Reggie-1/flotillin-2 (FLOT2) [90], a major component of lipid microdomains in membranes that can promote WNT secretion and diffusion [91]. Recent studies have revealed that high FLOT2 expression both mRNA and protein level predict poor outcomes in NSCLCs [92]. Such findings indicate that it is not just differential WNT expression but also WNT concentration at various points of its gradient, membrane availability of WNT ligands and endocytosis of specific WNT molecules can change during carcinogenesis, thus modulating cellular activity and potentially drug response.

**Posttranslational modifications of WNT pathway molecules in regulation of LC**

Secreted inhibitors and activators that regulate complex interactions within the complicated molecular network of WNT signaling [93] are under intense investigation. Epigenetic modulation, such as DNA methylation or histone deacetylation contributes to the deregulation of WNT signaling pathways. Down-regulation of several WNT signaling inhibitors have been reported in NSCLCs including AXIN, sFRPs 1–5, WIF-1, DKK-1, DKK-3, human homolog of Dapper (HDPR)1, runt-related transcription factor (RUNX)3, APC, caudal type homeobox (CDX)2, Dapper homolog (DACT)2, transmembrane protein (TMEM)88, Chibby, naked cuticle homolog (NKD1), empty spiracles homeobox (EMX)2, inhibitor of growth family (ING)4, and miR-487b. Although the mechanisms are not yet entirely clear, methylation and hypermethylation are the likely causes of reduced inhibitor levels [94, 95]. DACT 2 is one of the Dact gene family members, which inhibit canonical WNT signaling. If expression of DACT2 is lost due to hypermethylation of its promoter, then beta-catenin dependent signaling is no longer suppressed and uncontrollable proliferation ensues [96]. Similarly to

---

**Fig. 2** Mechanism of WNT secretion. WNT ligand is secreted in the endoplasmatic reticulum (ER) and palmitoylated by Porcupine (PORC). a After releasing from the ER palmitoylated WNT enters the Golgi apparatus and Wls-coupled WNT travels to the plasma membrane. Then Wls is recycled from the plasma membrane and the retromer complex shuttles it back to the Golgi. b WNT-Wls complex can be transferred to the microvesicular body. Exosome can be produced from MVB that serves as a source of WNTs for long-range spread. c Reggie-1/Flotillin-2 can mediate re-endocytosis of WNT molecules and may facilitate the transport of a more soluble micellar-like form of WNTs [89]
DACT2, GPC5 is downregulated in lung adenocarcinomas due to significant promoter hypermethylation. The methylation level of GPC5 promoter negatively correlates with its transcriptional expression and beta-catenin dependent signaling [97]. Restoration of its WNT pathway inhibitory function results in reduced WNT signaling, decreased cell proliferation, and increased apoptosis. Apart from promoter methylation of WNT pathway inhibitors, methylation of the beta-catenin promoter has also been described that leads to loss of beta-catenin protein expression and a poor prognosis in NSCLC patients [98].

Epigenetic modulation of the “anti-aging” Klotho [99] is also significant in carcinogenesis [100–102]. Klotho can act as an antagonist of the beta-catenin-dependent WNT signaling pathway; therefore overexpression of Klotho can reduce active beta-catenin and target c-myc and cyclin D1 levels [102], resulting in reduced proliferation. Supporting the above findings, down-regulation of Klotho increases cisplatin resistance while Klotho expression can attenuate resistance of LC to cisplatin-based chemotherapy and increase apoptosis [103]. Clinical survival analysis of various cancer types, however, has not demonstrated unequivocal involvement of Klotho in the carcinogenic process and it is still unclear whether the inconsistent role of Klotho in carcinogenesis is dependent on epigenetic variability or other factors [104, 105]. Recent discovery has exposed that apart from histone or DNA methylation of WNT signaling regulators, arginine methylation of the DVL-associated G3BP2 protein is a necessary post-translational modulation for LRP6 phosphorylation to initiate WNT3a induced canonical beta-catenin signaling from the receptor complex [106]. As WNT3a is one of the WNT ligands that promotes LC progression [107], investigation of methylation dependency of signaling molecules in the canonical signaling cascade can open up new therapeutic targets for drug discovery.

Methylation, however, is not the only posttranslational modification that modulates WNT signaling. AXIN, for example, can be destabilized by tankyraseas [108] that regulate protein interactions and protein stability by poly-ADP-ribosylation. The post-translational modification of the N-terminal region of histone, by acetylation, methylation, ubiquitination, phosphorylation, or sumoylation, regulates DNA transcription, replication and repair. Recent epigenetic and transcriptomic profiling of human primary alveolar epithelial cells during in vitro differentiation revealed interactions amongst known regulatory pathways of distal alveolar epithelial cell differentiation. Interactions amongst the WNT signaling pathways, the transforming growth factor beta (TGF-beta) pathway, the hepatocyte nuclear factor 4 alpha (HNF4A) and the retinoid X receptor (RXR) signaling pathway [109] were strongly dependent on posttranslational changes.

### MicroRNAs targeting WNT signaling and LC

The non-coding microRNAs or miRNAs suppress gene expressions by inhibiting translation or increasing degradation of target gene miRNAs [110]. miRNAs, similarly to WNT proteins and various lipophilic molecules are delivered to target cells mostly in extracellular vesicles that are shed into body fluids from a great variety of cells for secure “message” delivery. For diagnostic purposes, collecting cancer specific miRNAs from extracellular vesicles rather than serum is more reliable, as the extracellular vesicle protects miRNAs from degradation [111].

Several miRNAs have been identified in association with various types of LCs in recent years (Table 2). For example, down-regulation of miR-29 and let-7 were shown to be DNMT3A3B [112] and KRAS [113] targeting miRNAs, respectively, allowing upregulation of their targets. Meanwhile, KRAS, MYC, WNT5a, BMI1, and SUZ12 are targeted by miR-487b, which is down-regulated in certain types of LCs supporting the carcinogenic process [114]. Down-regulation of miR-214 levels was documented in cancer stem cells (CSCs) leading to stem cell marker expression including Nanog, OCT4, and SOX2 [115]. Amongst miR-214 targets in lung adenocarcinomas several beta-catenin-interacting proteins were also found [115], while beta-catenin itself was rather affected by miR-3619-5p. miR-3619-5p has been documented to suppress tumor growth in A549 and H460 NSCLC cell lines via binding to the 3′-UTR region of the beta-catenin gene [116]. Additionally, overexpression of miR-376c inhibits the growth of NSCLC cells via a WNT-related orphan nuclear receptor, the liver receptor homolog-1 (LRH-1) [117].

### Table 2 miRNAs regulating WNT signaling in LC

| miRNA  | Regulation                                      | References |
|--------|-------------------------------------------------|------------|
| miR-34a| Inhibits beta-catenin activity                   | [200]      |
| miR-17-92| Increases beta-catenin activity                  | [201]      |
| miR-21  | Increases beta-catenin expression                | [202]      |
| miR-27b | Upregulated by WNT5a, inhibits vascular branching| [134]      |
| miR-29  | Downregulates beta-catenin expression            | [203]      |
| miR-31  | Decreases WNT antagonists and increases WNT5a    | [119]      |
| miR-191 | Increases beta-catenin pathway activation        | [204]      |
| miR-374a| Targets WNT5a                                   | [205]      |
| miR-376c| Suppresses canonical WNT signaling               | [117]      |
| miR-410 | Activates beta-catenin pathway                   | [118]      |
| miR-487b| Reduces WNT5a activity                           | [114]      |
| miR-544a| Downregulates GSK3beta                          | [206]      |
| miR-574-5p| Enhances beta-catenin phosphorylation            | [207]      |
| miR-708 | Increases canonical WNT signaling                | [208]      |
In contrast, miR-410 can accelerate tumor growth by suppressing the expression of SLC34A2, a type 2b sodium-dependent phosphate transporter (NaPi-IIb) that is located in the apical membrane of ATII cells. Decreased NaPi-IIb levels have been shown to activate the WNT/beta-catenin pathway leading to enhanced tumor growth and invasion [118]. Perhaps not surprisingly, miRNA expression is also regulated by one of the primary causes of LCs, cigarette smoke. miR-31 for example that targets the WNT pathway inhibitor DKK1 is triggered by cigarette smoke leading to enhanced tumorigenesis in the lung [119].

Although some miRNAs have not been directly associated with WNT signaling in NSCLCs, in other tumor types they have been demonstrated to play important WNT pathway regulatory function. For example miR-148b suppresses tumor growth via inhibiting canonical WNT signaling in hepatocellular carcinoma [120], while miR-499 can stimulate blood vessel formation via WNT signaling activation in various other tumor types [121]. Their precise role in LCs awaits further investigation.

WNT signaling in LC angiogenesis

WNT signaling has a fundamental role in both normal and tumor angiogenesis [122]. The canonical WNT pathway can regulate cadherin junctions in endothelial cell connections and therefore vascular permeability [123, 124]. Additionally, WNT signaling controls trans-endothelial migration of tumor cells via beta-catenin-dependent regulation of endothelial VE-, E- and N-cadherin expression [123–125]. The WNT-Ca2+ pathway -which is often referred to as a pro-angiogenic signaling pathway- induces endothelial cell proliferation and enhances capillary network formation, while activation of the PCP WNT pathway coordinates endothelial cell migration [126]. Activation of the PCP pathway via FZD4 impairs vascular morphogenesis [127], while activation of downstream components, such as DAAM-1 can reverse the changes [126]. The WNT/PCP pathway is responsible for impaired pericyte motility and as pericytes are important components of vessel formation and integrity, the balance of WNT pathways are important in forming and maintaining a functional lung vasculature [128]. Any imbalances in canonical and non-canonical WNT signaling could, therefore, modulate blood vessel formation in tumors and consequently affect therapeutic responses.

Induction of neovascularization – Similarities and differences in LC subtypes

Cancer cells can induce neovascularization when the solid tumor reaches more than 2 mm in diameter [129] and hypoxia occurs in the inner center of the tumor. Intra-tumor angiogenesis is best characterized by micro-vessel density. Extensive vascularization and higher vessel density indicate disease progression and predict a poor outcome in NSCLCs [130]. Amongst several other pro-angiogenic factors like Hypoxia-Inducible Factor (HIF)1alpha [131], Vascular Endothelial Growth Factor (VEGF)-A is of vital importance for endothelial cell proliferation and motility [132]. The pro-angiogenic factors are under complex molecular regulation. VEGF-A for example is documented to be under beta-catenin-dependent, canonical WNT control via a PPAR-gamma dependent mechanism [133]. Interestingly, PPAR-gamma down-regulation that is essential for VEGF-A up-regulation, can also be induced by a WNT5a triggered miR27b dependent manner [134]. Although tumors including NSCLC subtypes use the same molecular components to attract the necessary cell types for blood vessel formation as normal tissues, tumor vessels are often leaky, poorly differentiated and not hierarchic. This is due to differential WNT expression induced modulation of cellular morphology and function leading even to cellular mimicry of cells in the resident vascular network [135, 136]. For instance, WNT5a signaling can induce vascular mimicry [137], while canonical pathway activation by WNT3a or WNT7b is associated with increased angiogenesis [138, 139].

Angiogenesis and WNT target genes: Matrix metalloproteinases

The canonical WNT pathway mediated EMT [140], which correlates with E-cadherin down-regulation [68] and VEGF-A up-regulation is associated with micrometastasis formation [141, 142]. Blood vessel formation in lung tumors, however, also need the WNT target proteolytic matrix metalloproteinase enzymes (MMPs) [143] that are responsible for degradation of the extracellular matrix components during new blood vessel formation or vessel branching. MMP-2, −3, −7 and MMP-9 have been shown to be important in NSCLCs [93] and angiogenesis in general [143]. One of the most studied enzymes is MMP-9 which degrades type IV collagen, modulates VEGF bioavailability through direct cleavage and also regulates vascular permeability [144]. In lung adenocarcinomas, MMP-9 levels correlate with increased risk of relapse [143, 145], although its direct regulation by canonical WNT3a signaling has only been studied in colorectal cancer [146]. MMP-7 is up-regulated by canonical WNT signaling and associated with increased invasion of LCs [147–149]. Additionally, up-regulation of MMP1 by the non-canonical WNT5a has also been shown in NSCLC [137]. Proteomic analysis of an Mmp1−/− mouse model revealed that tumor growth is hampered by the absence of MMP1 activity and is also associated with decreased levels of chitinase-3 like 3 (CHI3L3) and accumulation of the receptor for advanced glycation end-products (RAGE) and its ligand, S100A8 [150]. The molecules identified in the mouse model are important markers for lung development, aging and tumorigenesis. Upregulation of RAGE,
for example, is observed in type I alveolar epithelial cells (ATI) during lung development, which process is associated with reduced beta-catenin-dependent WNT signaling [151]. Interestingly, during aging RAGE is highly expressed [152], while in malignant lung tumors RAGE is down-regulated [153, 154]. More studies are needed to explain such differences and to identify the primary role of RAGE in aging normal lung tissue and in LC.

The angiogenic process as a therapeutic target
As the angiogenic process is a therapeutic target in solid tumors, anti-angiogenic agents have become important in therapy. The anti-VEGF-A monoclonal antibody, bevacizumab is the first approved antiangiogenic agent to be applied in NSCLCs [155]. Despite some success of anti-angiogenic agents in cancer treatment, the expected break-through in cancer therapy has not occurred. A randomized phase II study investigated the effect of bevacizumab mono- and paclitaxel-carboplatin-bevacizumab combination therapy. Although the latter combination increased progression free survival, serious hemorrhage was detected in some patients mostly with squamous histology [156]. As there is a well-documented difference in the WNT ligand profile of the two NSCLC subtypes [68], further studies of WNT controlled regulation of blood vessel formation is needed to more effectively stratify patients for the most appropriate anti-angiogenic treatment. The most worrying aspect is that in some cases – mostly in glioblastomas [157–160] - administration of anti-angiogenic drugs contributed to formation of even more invasive tumors and failure of cytotoxic treatment.

Maintenance of cancer stem cells and therapeutic resistance
The accumulation of highly chemotherapy resistant cancer stem cells (CSC) are thought to play an important role in the incurability of LCs [161]. In CSCs beta-catenin dependent canonical WNT signaling is highly active and helps to maintain CSCs that express putative stem cell markers such as octamer-binding transcription factor 4 (OCT4) [162], Leucine-Rich Repeat-containing G-protein coupled receptor 5 (LGR5/GPR49), CD44, CD24, EpCAM [163], and cyclin D1 [11, 162]. The above markers are associated with increased cell proliferation rate and clone formation efficacy [164]. Such CSCs are highly resistant to several chemotherapeutic drugs [164] due to overexpression of ATP-binding cassette (ABC) transporter protein G2 (ABCG2 or BCRP1) [165, 166] resulting in increased drug efflux [167]. Apart from ABCG2 the presence of other ATP-binding cassette (ABC) transporter family members, such as ABCB1 (MDR1 or Pgp) are frequently tested as they are responsible for chemotherapeutic drug removal from cancer cells. Recently, the canonical WNT pathway dependent beta-catenin target TCF/LEF transcription factors were shown to activate the ABCB1 promoter indicating that WNT signaling is involved in the regulation of efflux transporter expression [168]. Studies of ABCB1 revealed that paclitaxel and irinotecan - the two drugs often used in cisplatin or carboplatin combination therapy of LCs [169, 170] - are both substrates of ABCB1. Cisplatin, a widely used drug in LC therapy, can also activate the canonical WNT pathway [162] which may explain the increased expression of efflux drug transporters including ABCB1 and ABCG2 correlating with reduced survival of NSCLC [171] and SCLC patients [172]. In contrast, inhibition of the beta-catenin dependent WNT pathway by high serum levels of the canonical pathway inhibitor DKK1 [173] has been detected in patients suffering from NSCLC and esophageal carcinoma. Increase in DKK1 levels was also associated with resistance to platina-based chemotherapy [174]. Based on previous research data, the role of WNT signaling in ABC transporter regulation appears contradictory, therefore more studies are needed to understand the molecular regulation and to identify potential therapeutic targets in WNT pathway associated chemoresistance.

Although increased expression of drug transporters in chemoresistant lung tumors suggests that the drug transporters might be useful therapeutic targets, sadly, clinical trials using ABC transporter inhibitors have not been successful. For example, the ABCB1 (MDR1) inhibitors tariquidar and CBT-1(R) [175–177] were tested unsuccessfully in two phase III clinical studies where treatment of stage IIIB/IV NSCLC patients with tariquidar in combination with vinorelbine or carboplatin/paclitaxel did not show any advantages and the trial was finished prematurely (ID NCT00042302 and NCT00042315) [178]. Additionally, inhibitors of efflux transporters can seriously damage the non-cancerous stem cell pool by increasing toxicity and enhancing the serious side effects of such therapies [179].

Conclusions
Complex deregulation of WNT signaling is an important element of lung carcinogenesis, controlling not just the carcinogenic process, but also tumor vascularization, drug response and disease progression. While current cancer research frequently cites the importance of precision medicine, therapeutic approaches and even drug development are still strongly focused on genetic mutations [180]. Individual variations in genetic driver and passenger mutations, along with non-mutated but deregulated signaling pathway combinations receive less attention, but can be just as important. Novel drugs are therefore under development to interfere with molecules of the WNT signaling pathway. Recently, NSCLC patients have been recruited into a clinical trial (NCT01957007) testing an anti-FZD7 antibody (OMP18R5 or Vantictumab) in combination therapy [181].
Further studies, however, are also needed to show the effect of WNT pathway interference on tumor cells and non-tumor cells alike [182]. The WNT-receiving cells respond to WNT proteins in a concentration-dependent manner by activating different target genes. Simply, blocking a receptor therefore may result in different cellular response in tumor cells and non-tumor cells at various points of the WNT ligand concentration gradient. To understand such complexity, experimental models of human cancer tissues [183] are essential for future studies. This will allow us to expand our understanding of carcinogenesis beyond mutation analysis and allow intricate investigation of the tissue microenvironment and its effect on epigenetic signal modulation in carcinogenesis and therapeutic drug response.

Abbreviations

ABC: ATP-binding cassette; ABCB1: ATP-binding cassette transporter protein B1; ABCG2: ATP-binding cassette transporter protein G2; AC: adeno-carcinoma; AE: alveolar epithelium; AEC: alveolar epithelial cell; AK: alkanic lipoma kinase; AP: activator protein; APC: adenomatous polyposis coli; AT: alveolar type; AXIN: Axin inhibition protein; CaMKII: calcium calmodulin mediated kinase; CBP: CREB-binding protein; CDX: caudal type homeobox; CH3L3: chitinase-3 like 3; CREB: CAMP response element-binding protein; CSC: cancer stem cell; DAAM: disheveled associated activator of morphogenesis; DACT: Dapper homolog; DKK: Dickkopf-related protein; DMNT3A/3B: DNA methyltransferase 3 alpha/3 beta; DVL: Disheveled; E-cadherin: epithelial cadherin; EGFR: epidermal growth factor receptor; EMT: epithelial-mesenchymal transformation; EMK: empty spiracles homeobox; EPCAM: epithelial cell adhesion molecule; FGF: fibroblast growth factor; FLOT: flotillin; FRP: Frizzled-related protein; FZD: Frizzled receptor; GPC: glypican; GSK-3-beta: glycogen synthase kinase 3-beta; HDPR: human homolog of Dapper; HIF: hypoxia-inducible factor 1 alpha; HNF-4A: hepatocyte nuclear factor 4 alpha; IGF: insulin-like growth factor; IGFR: inhibitor of growth factor; JNK: Jun N-terminal kinase; LC: lung cancer; LCC: large cell carcinoma; LEF: lymphoid enhancer-binding factor; LGR: leucin-rich repeat containing G-protein coupled receptor; LGR5: lipoprotein receptor-related protein, miRNA: microRNA; MMP: matrix metalloproteinase; N-cadherin: neural cadherin; NFAT: nuclear factor of activated T-cell; NKD: naked cuticle homologue; NLK: nemo-like kinase; NSCLC: non-small cell lung cancer; OCT: octamer-binding transcription factor; P53: p53 protein; PPAR: peroxisome proliferator-activated receptor; RAC1: Ras-related C3 botulinum toxin substrate 1; RAGE: receptor for advanced glycation end-product; Rb: retinoblastoma protein; RhoA: Ras homologue gene family member A; ROCK: Rho-associate coiled-coil-containing protein 1; ROS2: receptor tyrosine kinase-like orphan receptor; RUNX: runt-related transcription factor; RXR: retinoid X receptor; RYK: receptor tyrosine kinase; SCC: squamous cell carcinoma; SLC: small cell lung cancer; SHH: sonic hedgehog; SLC: solute carrier transporter; STAT: signal transducer and activator of transcription; TAK: transforming growth factor beta-activated kinase; TCF: T-cell factor; TGFbeta: transforming growth factor beta; TMEM: transmembrane protein; VE-cadherin: vascular endothelial cadherin; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; WIF: WNT inhibitory factor; WNT: wingless/int

Acknowledgements

The authors are indebted to Prof Emerita Mary Keen, Department of Pharmacy and Therapeutics, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, UK and Mr. Ricky Odedra, University of Pecs, Hungary for discussions and language editing.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Funding

JEP was supported by the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2–11/1–2012-0001 ‘National Excellence Programme’. This work was also supported by the GINOP 2.3.2–15–2016–00022 grant. The project has been supported by the European Union, co-financed by the European Regional Development Fund.

Authors’ contributions

JR, LJ, GM, KK and JEP all performed literature search, have written specific sections of the manuscript. JR prepared the figures and finalized the reference list. JR and JEP have finalized the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Competing interests

The author(s) declare(s) that they have no competing interests.

Received: 22 December 2016 Accepted: 27 August 2017

Published online: 05 September 2017

References

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49–52.
2. Jemal A, Gogg L, Ward E, Ries LAG, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer [Internet]. 2004 [cited 2016 Jun 14];101:3–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15221985.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. [Internet]. 2015 Jul 16;59:225–249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19474385.
4. Ettenger DS, Akerley W, Bhoraghe H, Chang AC, Cheney RT, Chiriac LR, et al. Non-Small Cell Lung Cancer. J Natl Compr Canc Netw [Internet]. 2012 [cited 2015 Oct 21];10:1226–1271 Available from: http://www.jncn.org/content/10/10/1236.full.
5. Molina JR, Yang P, Cassivi SD, Sild S, Adel AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. [Internet]. 2008 [cited 2014 Nov 16];83:584–594 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2718421
6. D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. [Internet]. 2010 [cited 2015 Sep 12];21 Suppl 5:v116–v119 Available from: http://annonc.oxfordjournals.org/content/21/suppl_5/v116.full.
7. Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruyscher D, et al. Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer [Internet]. 2013 [cited 2015 Oct 18];82:275–282 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24049287.
8. He B, Barg RN, You L, Xu Z, Reguart N, Mikami I, et al. WNT signaling in stem cells and non-small cell lung cancer. Clin Lung Cancer [Internet]. 2005 [cited 2016 Jun 14];7:54–60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16098245.
9. Stewart DJ. WNT signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. [Internet]. 2014 [cited 2015 Jun 17];106:dxj736 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24309006.
10. Nuss R, Fuerer C, Ching W, Hamish K, Logan C, Zeng A, et al. WNT signaling and stem cell control. Cold Spring Harb. Symp. Quant. Biol. [Internet]. 2008 [cited 2016 Oct 23];59:59–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19029888.
11. Matieres J, He B, You L, Xu Z, Jablons DM. WNT signaling in lung cancer. Cancer Lett. [Internet]. 2005 [cited 2016 Jun 14];222:1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15837535.
12. Gao C, Xiao G, Hu J. Regulation of WNT/B-catenin signaling by posttranslational modifications. Cell Biosci. [Internet]. 2014 [cited 2017 Apr 10];4:13 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24594309.
13. Li C, Chen H, Hu L, Xing Y, Sasaki T, Villous MF, et al. Ror2 modulates the canonical WNT signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol. Biol. [Internet]. BioMed Central; 2008;9:11 Available from: http://bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-9-11. [cited 2016 Jun 14].
51. Hashimoto S, Chen H, Que J, Brockway BL, Drake JA, Snyder JC, et al. 
β-Catenin-SOX2 signaling regulates the fate of developing airway epithelium. J. Cell Sci. [Internet]. 2012 [cited 2016 Jun 14];125:932–942. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22421361.

52. Venesio T, Balsamo A, Scordamaglia A, Bertolasi M, Arrigoni A, Sprujevik T, et al. Gli/herk4 APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas. Mod. Pathol. [Internet]. 2003 [cited 2016 Jun 14];16:157–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12527714.

53. Kotinas A, Evangelou K, Zacharatos P, Kittas C, Gougouli VG. Proliferation, but not apoptosis, is associated with distinct β-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(0)/G(1)-S phase cell-cycle regulators. Am. J. Pathol. [Internet]. 2002 [cited 2016 Jun 14];161:1619–1634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12414510.

54. Sekine S, Shibata T, Matsuno Y, Maeshima A, Iishi G, Sakamoto M, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol. [Internet]. 2003 [cited 2016 Jun 14];202:214–221. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12754743.

55. Oghaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurren MO. APC mutations are infrequent but present in human lung cancer. Cancer Lett. [Internet]. 2004 [cited 2016 Jun 14];207:197–203. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15072829.

56. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, et al. β-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 2014;74(20):5891-902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25164010.

57. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer [Internet]. 2001 [cited 2016 Jun 14];85:64–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11437403.

58. Blanco D, Vicent S, Elzaga E, Pino I, Fraga MF, Esteller M, et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest. [Internet]. 2004 [cited 2016 Jun 14];84:999–1012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15195114.

59. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, et al. Altered HOX gene expression and canonical and up-regulation of non-canonical WNT signalling in the carcinogenic process of squamous cell lung carcinoma. PLoS One [Internet]. 2013 [cited 2015 Jul 20];8:e57391 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3591436&tool=pmcentrez&rendertype=abstract.

60. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsui S, Nagayama M. Down-regulation of WNT-4 and up-regulation of WNT-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci. [Internet]. 2003 [cited 2016 Jun 14];94:593–597. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12841867.

61. Brabletz T, Hubek F, Spaderna S, Schmalhofer O, Hiendtmeier F, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs [Internet]. 2005 [cited 2016 Jun 14];179:965–974. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15492193.

62. Nakano T, Tani M, Ishibashi Y, Kimura K, Park Y-H, Imaizumi N, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis [Internet]. 2003 [cited 2016 Jun 14];20:665–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12669798.

63. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer [Internet]. 1996 [cited 2016 Jun 14];73:1401–1408. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8645587.

64. McCawley LJ, Crawford HC, King LE, Muddett J, Mattrissan LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. [Internet]. 2004 [cited 2016 Jun 14];64:6965–6972. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15461618.

65. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the WNT pathway in non small cell lung cancer: evidence of dishevelled overexpression, Oncogene [Internet]. 2003 [cited 2016 Jun 14];22:7218–7221. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12462050.

66. Nozaki I, Tsuchi Y, Iijima O, Ohmura Y, Andou A, Miyazaki M, et al. Reduced expression of BRCA1/Brk-3 gene in non-small cell lung cancer. Int J Oncol. [Internet]. 2001 [cited 2016 Jun 14];19:117–121. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11408931.

67. Wissmann C, Wild PJ, Kaiser S, Roepecke S, Stoehr R, Woenckhaus M, et al. WIFI1, a component of the WNT pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol. [Internet]. 2003 [cited 2016 Jun 14];201:204–212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12706537.

68. Matiezer J, He B, You L, Xu Z, Lee AY, Mikami I, et al. WNT inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Res. [Internet]. 2004 [cited 2016 Jun 14];64:6965–6972. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15461618.

69. Lee AY, He B, You L, Daldray S, Xu Z, Matiezer J, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene [Internet]. 2004 [cited 2016 Jun 14];23:6672–6676. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15220104.

70. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 18 associated with risk for adenocarcinoma. Am J Hum Genet. [Internet]. Elsevier; 2009 [cited 2017 May 5];85:579–691. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19836005.

71. Marshall AL, Christiansen DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis [Internet]. 2013 [cited 2017 May 5];34:487–502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23349013.

72. Roman J, Koval M. Control of lung epithelial growth by a nicotinic acetylcholine receptor: the other side of the coin. Am J Pathol. [Internet]. 2003 [cited 2017 May 5];163:479–495. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12841867.

73. Sakurai R, Cerny LM, Torday JS, Rehan VK. Mechanism for nicotine-induced up-regulation of WNT signaling in human alveolar interstitial fibroblasts. Exp Lung Res [Internet]. 2011 [cited 2017 May 12];37:144–154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21133803.

74. Sasaki T, Gan EC, Wakeham A, Kombuth S, Mak TW, Okada H. HLA-B-associated transcript 3 (Bat3)/Slythe is essential for p530-mediated...
87. Willert K, Nusse R. WNT proteins. Cold Spring Harb Perspect Biol [Internet].
86. Bradley RS, Brown AM. The proto-oncogene int-1 encodes a secreted
92. Wang Y-L, Yao W-J, Guo L, Xi H-F, Li S-Y, Wang Z-M. Expression of flotillin-2 in
90. Arkhipova KA, Sheyderman AN, Laktionov KK, Mochalnikova V V,
85. Li Y, Sheu C-C, Ye Y, de Andrade M, Wang L, Chang S-C, et al. Genetic variants
84. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT
99. Kuro-o M. Klotho and the aging process. Korean J Intern Med. [Internet].
98. Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y,
94. Stewart DJ. WNT signaling pathway in non-small cell lung cancer. J Natl
90. Macfarlane L-A, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer.
607. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755751.
330. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25023701.
98. Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y,
94. Stewart DJ. WNT signaling pathway in non-small cell lung cancer. J Natl
90. Macfarlane L-A, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer.
607. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755751.
330. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25023701.
98. Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y,
94. Stewart DJ. WNT signaling pathway in non-small cell lung cancer. J Natl
90. Macfarlane L-A, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer.
607. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25755751.
330. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25023701.
98. Miao Y, Wang L, Zang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y,
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cancer cells. 

Reynolds PR, Kasterel SD, Cosio MG, Sturrock A, Huecksteat T, Hoidal JR. 
RAGE: developmental expression and positive feedback regulation by Egfr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008 [cited 2016 Jun 14];294(4):L1049-L1101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18390831.

Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis [Internet]. 2005 [cited 2016 Jun 14];26:299–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17357979.

Spanswer LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med [Internet]. 2009 [cited 2016 Jun 14];7:17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19292913.

Gindelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist [Internet]. 2007 [cited 2015 Oct 27];12:1183–1193. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17962612.

Johnson DH, Feihenbacher L, Novotny VF, Hersbt RS, Nemunaitis J, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol [Internet]. 2004 [cited 2015 Aug 12];22:1984–1991. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15169807.

Van der Veldt AAM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter W. MDM2, ARF, and p53: a metabolic hub for therapy resistance in cancer cells. Respiratory Research [Internet]. 2011 [cited 2016 Jun 14];12:65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21986642.

Kumar S, Arbab AS. Neovascularization in glioblastoma: Current Pitfall in Antiangiogenic therapy. Zhong liu za zhi [Internet]. 2013 [cited 2016 Mar 23];1:16–19. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4073792&tool=pmcentrez&rendertype=abstract

Pazé-Ribes M, Allen E, Hudoock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell [Internet]. Elsevier; 2012 [cited 2016 Mar 21];21:182–191. Available from: http://www.sciencedirect.com/science/article/pii/S1535610810004464.

Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small-cell and small-cell lung cancer. Crit Rev Oncol Hematol [Internet]. 2001 [cited 2016 Jun 14];37:8–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1193.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, et al. Quantitative assessment of the WNT/beta-catenin pathway signaling in solid tumors. BMC Cancer [Internet]. BioMed Central; 2015 [cited 2016 Jun 14];15:628 Available from: http://www.biomedcentral.com/articles/10.1186/s12885-015-0635-9

Spencer LA, Hikko T, Kasei M, Furukawa Y, Nakamura Y, Suzuki Y, et al. DKK1, a negative regulator of WNT signaling, is a target of the beta-catenin/TCF pathway. Oncogene [Internet]. 2004 [cited 2016 Jun 14];23:8520–8526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15378202.

Agrawal M, Abraham J, Balis FM, Edgeler M, Stein WD, Bates S, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res. [Internet]. 2003 [cited 2016 Jun 14];9:650–656. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12756431.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist CBT-1 in patients with small-cell lung cancer cell lines. BMC Cancer [Internet]. BioMed Central; 2015 [cited 2016 Oct 21];15:628 Available from: http://www.biomedcentral.com/articles/10.1186/s12885-015-0635-9

Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, et al. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist [Internet]. 2012 [cited 2016 Jun 14];17:512. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22416063.

Rapp et al. Respiratory Research (2017) 18:167
